Clinical trial
Phase I/II Trial of Encorafenib, Binimetinib, and Nivolumab in Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
NCT04044430 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I/II Trial of Encorafenib, Binimetinib, and Nivolumab in Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
- Lead sponsor
- University of California, San Francisco
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- August 31, 2020
- Completion date
- July 31, 2022
- Enrollment
- 2 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic colon adenocarcinoma, metastatic colorectal adenocarcinoma, metastatic microsatellite stable colorectal carcinoma, metastatic rectal adenocarcinoma, stage iii colon cancer, stage iii colorectal cancer, stage iii rectal cancer, stage iiia colon cancer, stage iiia colorectal cancer, stage iiia rectal cancer, stage iiib colon cancer, stage iiib colorectal cancer, stage iiib rectal cancer, stage iiic colon cancer, stage iiic colorectal cancer, stage iiic rectal cancer, stage iv colon cancer, stage iv colorectal cancer, stage iv rectal cancer, stage iva colon cancer, stage iva colorectal cancer, stage iva rectal cancer, stage ivb colon cancer, stage ivb colorectal cancer, stage ivb rectal cancer, stage ivc colon cancer, stage ivc colorectal cancer, stage ivc rectal cancer